STEVE ASELAGE Insider Trading $BCRX BIOCRYST PHARMACEUTICALS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for STEVE ASELAGE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of STEVE ASELAGE. STEVE ASELAGE is Director in BIOCRYST PHARMACEUTICALS INC ($BCRX) and EVP, Global Commercial Ops in CTI BIOPHARMA CORP ($CTIC) and in Acer Therapeutics Inc. ($OPXA) and Director in Acer Therapeutics Inc. ($OPXA) and Chief Executive Officer in Retrophin, Inc. ($RTRX) and Director in Retrophin, Inc. ($RTRX).
STEVE ASELAGE in BIOCRYST PHARMACEUTICALS INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of STEVE ASELAGE: Director
Holdings: 31,496 shares
Current Value: $178,582
Latest Transaction: Mar 02 2021
$BCRX Market Capitalization: $427.06M
$BCRX Previous Close: $5.67
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of STEVE ASELAGE in BIOCRYST PHARMACEUTICALS INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACER, BCRX, CTIC, RTRX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 02 2021 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 10.78 | 927 | 9,993 | 31,496 | 30.6 K to 31.5 K (+3.03 %) |
| Mar 02 2021 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 10.78 | 927 | 9,993 | 31,496 | 30.6 K to 31.5 K (+3.03 %) |
| Dec 02 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 5.11 | 1,956 | 9,995 | 30,569 | 28.6 K to 30.6 K (+6.84 %) |
| Sep 02 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 4.15 | 2,409 | 9,997 | 28,613 | 26.2 K to 28.6 K (+9.19 %) |
| May 14 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Option Exercise | A | 5.41 | 40,000 | 216,400 | 40,000 | |
| Mar 03 2020 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 3.00 | 1,666 | 4,998 | 25,092 | 23.4 K to 25.1 K (+7.11 %) |
| Dec 03 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 2.85 | 1,754 | 4,999 | 23,426 | 21.7 K to 23.4 K (+8.09 %) |
| Nov 18 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 1.45 | 15,000 | 21,750 | 21,672 | 6.7 K to 21.7 K (+224.82 %) |
| Sep 04 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Grant | A | 2.99 | 1,672 | 4,999 | 6,672 | 5 K to 6.7 K (+33.44 %) |
| May 24 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 3.57 | 3,000 | 10,710 | 5,000 | 2 K to 5 K (+150.00 %) |
| Mar 14 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Buy | P | 8.30 | 2,000 | 16,600 | 2,000 | 0 to 2 K |
| Jan 08 2019 | BCRX | BIOCRYST PHARMACEU ... | ASELAGE STEVE | Director | Option Exercise | A | 8.62 | 25,000 | 215,500 | 25,000 |
Page: 1